Novel GLP‐1 mimetics developed to treat type 2 diabetes promote progenitor cell proliferation in the brain
- 10 January 2011
- journal article
- research article
- Published by Wiley in Journal of Neuroscience Research
- Vol. 89 (4), 481-489
- https://doi.org/10.1002/jnr.22565
Abstract
One of the symptoms of diabetes is the progressive development of neuropathies. One mechanism to replace neurons in the CNS is through the activation of stem cells and neuronal progenitor cells. We have tested the effects of the novel GLP‐1 mimetics exenatide (exendin‐4; Byetta) and liraglutide (NN2211; Victoza), which are already on the market as treatments for type 2 diabetes, on the proliferation rate of progenitor cells and differentiation into neurons in the dentate gyrus of brains of mouse models of diabetes. GLP‐1 analogues were injected subcutaneously for 4, 6, or 10 weeks once daily in three mouse models of diabetes: ob/ob mice, db/db mice, or high‐fat‐diet‐fed mice. Twenty‐four hours before perfusion, animals were injected with 5′‐bromo‐2′‐deoxyuridine (BrdU) to mark dividing progenitor cells. By using immunohistochemistry and stereological methods, the number of progenitor cells or doublecortin‐positive young neurons in the dentate gyrus was estimated. We found that, in all three mouse models, progenitor cell division was enhanced compared with nondiabetic controls after chronic i.p. injection of either liraglutide or exendin‐4 by 100–150% (P < 0.001). We also found an increase in young neurons in the DG of high‐fat‐diet‐fed mice after drug treatment (P < 0.001). The GLP‐1 receptor antagonist exendin(9–36) reduced progenitor cell proliferation in these mice. The results demonstrate that GLP‐1 mimetics show promise as a treatment for neurodegenerative diseases such as Alzheimer's disease, because these novel drugs cross the blood–brain barrier and increase neuroneogenesis.Keywords
This publication has 44 references indexed in Scilit:
- Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer diseaseProceedings of the National Academy of Sciences of the United States of America, 2009
- Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's diseaseBehavioural Brain Research, 2009
- A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db / db miceProceedings of the National Academy of Sciences of the United States of America, 2007
- Mechanisms of action of glucagon-like peptide 1 in the pancreasPharmacology & Therapeutics, 2006
- The Leptin-Deficient (ob/ob) MouseDiabetes, 2006
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent.Current Alzheimer Research, 2006
- Long-Term Potentiation Enhances Neurogenesis in the Adult Dentate GyrusJournal of Neuroscience, 2006
- Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer's diseaseJournal of Alzheimer's Disease, 2005
- Amyloid-Associated Neuron Loss and Gliogenesis in the Neocortex of Amyloid Precursor Protein Transgenic MiceJournal of Neuroscience, 2002